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Aims We questioned whether prior cardiovascular disease has the same impact on risk
of cardiovascular events as type 2 diabetes, and whether this differed between men
and women.
Methods and results To address these issues we compared the 10-year risk of
cardiovascular events among 208 Caucasian individuals with diabetes to that of 2253
Caucasian individuals without diabetes, in a population-based cohort study. Gender
significantly modified the association between type 2 diabetes and cardiovascular
events (p=0.01). The hazard ratio of cardiovascular events associated with the
presence of diabetes was higher in women (adjusted hazard ratio, 1.8; 95% CI, 1.2 to
2.7) than in men (adjusted hazard ratio, 1.3; 0.9 to 2). As compared to men without
diabetes but with prior cardiovascular disease, risk of cardiovascular events was
significantly lower in men with diabetes but without prior cardiovascular disease
(adjusted hazard ratio, 0.5; 0.3 to 0.9). In contrast, this risk was equal in women with
diabetes but without prior cardiovascular disease and women without diabetes but
with prior cardiovascular disease (adjusted hazard ratio, 1.0; 0.6 to 1.7; P for
interaction between gender and diabetes=0.05).
Conclusions Women with diabetes but without prior cardiovascular disease have a risk
of cardiovascular events that is similar to that of women without diabetes but with
prior cardiovascular disease, whereas in men the presence of prior cardiovascular
disease conferred a higher risk. These data emphasise the necessity of aggressive
treatment of cardiovascular risk factors in women with type 2 diabetes.
© 2003 The European Society of Cardiology. Published by Elsevier Ltd. All rights
reserved.
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Introduction
Type 2 diabetes increases the risk of cardiovascular mor-
tality by a factor of 1.5 to 4.1–3 Patients with both
diabetes and prior cardiovascular disease have a particu-
larly poor prognosis.4 According to Haffner et al.,
patients with diabetes but without prior myocardial
infarction have a risk of fatal coronary heart disease that
is similar to that of patients without diabetes who have
survived a myocardial infarction.5 Therefore, Haffner
et al. conclude that, with regard to cardiovascular risk
factors, all patients with diabetes could be treated as if
they had prior coronary heart disease.
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This concept is elegant and appealing. However, it is
not clear whether Haffner et al.’s findings, which were
obtained in Finnish individuals, can be generalised to
other populations. First, studies do not concur quantita-
tively concerning the increased mortality risk associated
with type 2 diabetes.5–11 Relative mortality risks may
vary substantially with ethnicity,6,7 but even among
ethnically similar populations different relative mortality
risks have been reported.8–11 Second, studies often have
not distinguished between men and women, whereas
diabetes is reported to have a greater impact on mor-
tality risk in women than in men.3,12,13 This specifically
raises the question whether Haffner et al.’s findings5 are
valid in both men and women with type 2 diabetes. In
fact, we have not been able to find reports in which
relative mortality risks associated with type 2 diabetes
have been analysed stratified for gender as well as for the
presence of prior cardiovascular disease.
The aim of the present study, therefore, was to com-
pare the risk of cardiovascular events among four subsets
of participants: (1) individuals without diabetes or prior
cardiovascular disease, (2) individuals without diabetes
but with prior cardiovascular disease, (3) individuals
with diabetes but without prior cardiovascular disease,
and (4) individuals with both diabetes and cardio-
vascular disease. In addition, we assessed whether these
comparisons were affected by gender.
Methods
The Hoorn Study is a Dutch population-based cohort study of
glucose intolerance and cardiovascular risk, which began in
1989. The study population and baseline measurements have
been described in detail.14,15 Briefly, a random sample of 3553
men and women aged 50–75 years was selected from the popu-
lation register of the town of Hoorn; 2540 individuals (71%)
agreed to participate. A total of 56 non-Caucasians and 23
participants with missing variables were excluded from the
study, which resulted in a study population of 2461 participants.
All participants gave their written informed consent. The ethics
committee of the University Hospital Vrije Universiteit approved
the study.
Baseline measurements
A fasting blood sample was taken from all participants and
subsequently, a 75-g oral glucose tolerance test was adminis-
tered. A glucose dehydrogenase method (Merck, Darmstadt,
Germany) was used to determine fasting and 2-h postload
plasma glucose levels. Participants were classified as having
type 2 diabetes according to the 1985 World Health Organization
criteria.16 Serum lipids and lipoproteins were determined
by means of enzymatic techniques (Boehringer-Mannheim,
Mannheim, Germany) as described previously.15
Blood pressure was measured twice on the right arm with
participants in the sitting position, by means of a random-zero
sphygmomanometer (Hawksley-Gelman Ltd, Lancing, United
Kingdom). Participants were classified as having hypertension if
the mean systolic blood pressure was 160 mmHg or more, if the
mean diastolic blood pressure was 95 mmHg or more, and/or if
using anti-hypertensive medication. Body-mass index was
calculated as body weight divided by the square of the height
(kg/m2). Smoking status was classified as nonsmoker, former
smoker, or current smoker of cigarettes. Information about prior
cardiovascular disease was obtained using a standardized ques-
tionnaire including a translated questionnaire from the London
School of Hygiene.17,18 Participants were regarded as having
prior cardiovascular disease if they had a history of one or more
of the following: acute myocardial infarction, coronary bypass
surgery or angioplasty, angina pectoris, transient ischaemic
attack or stroke, intermittent claudication, or the use of
nitrates.
Follow-up
Data on the participants’ vital status on 1 January 2000 were
collected from the mortality register of the municipality of
Hoorn. For all participants who died, the cause of death was
extracted from the medical records of the general practitioner
and the hospital of Hoorn. For participants who moved out of
Hoorn, we obtained information on mortality from the new
municipality. Information about nonfatal cardiovascular events
was obtained from medical records of the hospital of Hoorn. The
ninth edition of the International Classification of Diseases (ICD)
was used to code the causes of death.19 Cardiovascular mortality
was defined as ICD codes 390-459 (‘Diseases of the circulatory
system’) or 798 (‘Sudden death, cause unknown’), because
sudden death in general is of cardiovascular origin.20 A custom-
ised and computerised classification system, based on existing
systems, was used to classify cardiovascular events.21–25 Cardio-
vascular events were defined as coronary heart disease (defined
by the presence of prolonged typical chest pain, ECG changes,
enzymes, and percutaneous transluminal angioplasty or cor-
onary artery bypass grafting), congestive heart failure, transient
ischaemic attack or stroke, or peripheral atherosclerotic
disease.
Cardiovascular events (n=341) were defined as the first fatal
or nonfatal cardiovascular event during follow-up. Seventeen
participants (0.6%) were lost to follow-up. We did not receive
information about nonfatal cardiovascular events from 612
(24.6%) participants, because they did not give permission or
had moved out of Hoorn (185 participants, 7.4%). However,
participants who were lost to follow-up did not differ impor-
tantly from the rest of the cohort with respect to cardiovascular
risk factors at baseline (Table 1). Follow-up duration was
defined as the period between the baseline examinations and
the end-points death, first nonfatal cardiovascular event, or the
date of leaving the area, loss to follow-up or 1 January 2000.
Statistical analyses
Our aim was to compare the risk of cardiovascular events in
individuals with type 2 diabetes to that of individuals without
diabetes with and without prior cardiovascular disease, and to
assess whether these comparisons were affected by gender.
Hazard ratios and 95% confidence intervals were calculated
by means of Cox proportional hazards model. Individuals with
missing values for morbidity were omitted from analyses with
nonfatal events as an endpoint. If a participant developed a
cardiovascular event and died after the next event, we used the
follow-up time until the first event, except in the separate
analyses of fatal cardiovascular events. In initial analyses we
considered the following possible determinants of cardiovascu-
lar events: age, diabetes, prior cardiovascular disease, gender
and the interaction term of the variables gender and diabetes.
Analyses were done with adjustment for age and without (model
1) and with (model 2) adjustment for other potentially con-
founding variables, namely low-density lipoprotein and high-
density lipoprotein cholesterol concentration, triglyceride
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concentration, presence of hypertension, and smoking status.
All analyses were performed with SPSS 10.1 for Windows 95.
Variables measured on a continuous scale were used as such in
the regression models.
Results
At baseline, the cohort consisted of 90 men with and 1044
men without diabetes, and of 118 women with and 1209
women without diabetes. Three hundred eighty-nine
individuals had prior cardiovascular disease (205 men and
184 women): myocardial infarction (n=135); coronary
surgery or angioplasty (n=79); angina pectoris (n=134);
transient ischaemic attack or stroke (n=110); intermit-
tent claudication (n=25); and/or use of nitrates (n=92).
(Twelve individuals had nitrate use as their only cri-
terion.) Table 2 shows gender-specific clinical character-
istics of the individuals according to their diabetic status
and history of cardiovascular disease. After up to 10.2
years of follow-up (median, 8.8; range, 9 days to 10.2
years), the cardiovascular death rate was 1.8 per 100
person years (n=12) for men with and 0.9 (n=79) for men
without diabetes, versus 2.4 (n=22) for women with and
0.4 (n=37) for women without diabetes. The rate of
cardiovascular events (fatal or nonfatal) was 5.1 per 100
person years (n=30) for men with and 2.8 (n=225) for men
without diabetes, versus 4.8 (n=38) for women with and
1.3 (n=134) for women without diabetes. Among women
with diabetes, the first event during follow-up was non-
fatal in 28 and fatal in 10 of 38; 12 fatal events were
preceded by a nonfatal event. Among men with diabetes,
the first event during follow-up was nonfatal in 23 and
fatal in seven of 30; five fatal events were preceded by a
nonfatal event.
In Cox regression analyses, gender modified the
association between diabetes and cardiovascular events
(P for interaction among gender and diabetes=0.01).
Therefore, we performed all analyses for men and
women separately. Fig. 1 shows the Kaplan–Meier esti-
mates of the proportion of participants without cardio-
vascular events during follow-up. The proportion of
participants with a cardiovascular event was highest
among men and women with both diabetes and prior
cardiovascular disease and lowest among individuals with
no diabetes or prior cardiovascular disease. Men with
diabetes but without prior cardiovascular disease, how-
ever, had a lesser risk of cardiovascular events than did
men without diabetes but with prior cardiovascular dis-
ease. In contrast, women with diabetes but without prior
cardiovascular disease had a risk of cardiovascular events
that was similar to that of women without diabetes but
with prior cardiovascular disease.
The age-adjusted hazard ratio of cardiovascular
events associated with the presence of diabetes, regard-
less of the presence of prior cardiovascular disease, was
1.5 (95% CI, 1.1 to 2.3) in men and 2.6 (95% CI, 1.9 to 3.8)
in women. After adjustment for low-density lipoprotein
and high-density lipoprotein cholesterol concentration,
triglyceride concentration, presence of hypertension and
smoking status, these hazard ratios were 1.3 (95% CI, 0.9
to 2) and 1.8 (95% CI, 1.2 to 2.7). Table 3 shows the
hazard ratios of cardiovascular events associated with
diabetes and prior cardiovascular disease for men and
women, with individuals with no diabetes or cardiovascu-
lar disease as the reference group. Among both men and
women, prior cardiovascular disease, regardless of the
presence of diabetes, was associated with an increased
risk of cardiovascular events (adjusted hazard ratios for
Table 1 Baseline characteristics of the participants and the participants who were lost to follow-up
Participants Participants lost to follow-up p-value of difference between the groups
Gender (% men) 47.7 40.2 0.001
Age (year) 61.7±7.3 61.8±7.5 0.8
Diabetes (%) 8.5 8.1 0.7
Newly diagnosed diabetes
(% of participants with diabetes)
54.1 65.3 0.2
Diabetes duration (year)a 6.4 (2.8–13.5) 5.9 (2.4–15.8) 1.0
HbA1c (%) 5.5±0.9 5.5±0.8 0.5
Prior cardiovascular disease (%) 16.2 14.6 0.4
Body-mass index 26.5±3.4 26.9±4.1 0.03
Systolic blood pressure (mmHg) 135.5±20.4 135.1±19.9 0.7
Diastolic blood pressure (mmHg) 82.2±10.3 81.2±10.5 0.4
Hypertension (%) 32.2 30.2 0.5
Total cholesterol (mmol/l) 6.6±1.2 6.7±1.3 0.04
HDL cholesterol (mmol/l) 1.3±0.4 1.3±0.4 0.7
LDL cholesterol (mmol/l)b 4.6±1.1 4.7±1.2 0.03
Triglycerides (mmol/l) 1.4 (1.0–1.9) 1.4 (1.0–2.0) 0.6
Smoking status (%)
Never/former/current 34.0/30.2/35.8 35.5/35.0/29.5 0.05
Data are presented as mean±standard deviation, median (interquartile range) or number (percentage). HDL=high-density lipoprotein, LDL=low-
density lipoprotein.
aAmong those with a prior diagnosis of diabetes.
bThe Friedewald formula was used to calculate low-density lipoprotein if triglyceride level was <4.5 mmol/l.
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Table 2 Baseline characteristics stratified for gender, history of cardiovascular disease and presence of type 2 diabetes
Non-diabetic men Men with Type 2 diabetes Non-diabetic women Women with type 2 diabetes
No prior CVD
(n=866)
Prior CVD
(n=178)
No prior CVD
(n=63)
Prior CVD
(n=27)
No prior CVD
(n=1053)
Prior CVD
(n=156)
No prior CVD
(n=90)
Prior CVD
(n=28)
Age (year) 60.6±7.2 63.4±7.1 63.8±6.9 65.0±7.1 61.2±7.3 64.1±7.1 66.0±6.6 69.0±4.9
Body-mass index 26.0±3.0 26.2±2.6 27.4±3.3 27.5±3.3 26.5±3.8 27.2±3.9 29.1±5.0 31.2±5.1
Systolic blood pressure (mmHg) 134.1±18.7 136.9±20.3 146.0±20.2 142.1±20.1 133.9±20.7 136.5±21.3 145.9±20.5 148.1±19.9
Diastolic blood pressure (mmHg) 83.4±9.9 83.6±9.8 87.3±10.8 81.5±10.8 80.7±10.7 80.6±10.4 82.8±9.4 80.6±10.5
Hypertension (%) 22.2 57.6 46.0 77.8 26.4 54.5 60.0 78.6
Antihypertensive medication (%) 9.5 48.9 20.6 63.0 15.5 50.6 37.8 75.0
Hypo-lipidaemic medication (%) 0.7 4.5 0 3.7 0.7 6.4 2.2 0
Total cholesterol (mmol/l) 6.4±1.1 6.7±1.0 6.2±1.2 6.4±1.1 6.9±1.2 7.0±1.2 6.9±1.5 6.8±1.0
HDL cholesterol (mmol/l) 1.2±0.3 1.1±0.3 1.1±0.3 1.1±0.2 1.5±0.4 1.4±0.4 1.2±0.3 1.1±0.2
LDL cholesterol (mmol/l)a 4.5±1.0 4.7±1.0 4.1±1.2 4.3±1.0 4.7±1.2 4.8±1.2 4.6±1.2 4.7±0.9
Triglycerides (mmol/l) 1.4 (1.0–1.9) 1.6 (1.2–2.2) 1.6 (1.2–2.5) 2.5 (1.8–3.1) 1.3 (1.0–1.7) 1.4 (1.1-2.0) 1.9 (1.4-2.8) 2.3 (1.7-3.1)
HbA1c (%) 5.4±0.5 5.5±0.5 6.9±1.7 7.2±1.6 5.3±0.5 5.5±0.5 7.2±1.9 7.5±1.9
Smoking status (%)
Never/former/current 17.5/45.6/36.9 8.4/56.2/35.4 17.7/59.7/22.6 11.5/46.2/42.3 48.6/22.5/28.9 51.3/25.6/23.1 61.4/18.2/20.5 53.6/17.9/28.6
Newly diagnosed diabetes (%) — — 65 52 — — 58 40
Diabetes duration (year)b — — 7.0 (4.6–11.3) 6.7 (2.6–14.5) — — 5.6 (2.2–14.2) 6.5 (2.6–13.5)
Data are presented as mean±standard deviation, median (interquartile) or number (percentage). CVD=cardiovascular disease, HDL=high-density lipoprotein, and LDL=low-density lipoprotein.
aThe Friedewald formula was used to calculate low-density lipoprotein if triglyceride level was <4.5 mmol/l.
bAmong those with a prior diagnosis of diabetes.
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men and women without diabetes, 2.2 and 2.0; for men
and women with diabetes, 4.3 and 3.8). In contrast,
among individuals without prior cardiovascular disease,
the presence of diabetes was strongly associated with
cardiovascular events among women (adjusted hazard
ratio, 2.0), but less so among men (adjusted hazard ratio,
1.3; Table 3).
When analyses were performed for fatal and non-
fatal cardiovascular disease separately, the results for
men were similar (adjusted hazard ratios, 1.2 and 1.2;
Table 3). However, for women with diabetes the hazard
ratio for fatal cardiovascular events was markedly higher
than that for nonfatal events (adjusted hazard ratios, 5.1
and 1.7; Table 3).
Table 4 illustrates that, as compared to individuals
without diabetes but with prior cardiovascular disease,
the hazard ratio for a cardiovascular event was lower
in men with diabetes but without prior cardiovascular
disease (adjusted hazard ratio, 0.5; 95% CI, 0.3 to 0.9),
but equal in women with diabetes but without prior
cardiovascular disease (adjusted hazard ratio, 1.0; 95%
CI, 0.6 to 1.7; P for interaction between gender and
diabetes=0.05).
When analyses were performed for fatal and nonfatal
cardiovascular events separately, the results for men
were again similar (adjusted hazard ratios, 0.4 and 0.5;
Table 4). Again, for women with diabetes the hazard
ratio for fatal cardiovascular events was higher than that
for nonfatal events (adjusted hazard ratios, 1.7 and 0.9;
Table 4).
Additional analyses
Analyses with prior myocardial infarction instead of prior
cardiovascular disease did not clearly change the results.
Among men, fully adjusted hazard ratios for cardiovascu-
lar events were 1.9 (1.3–2.7) among DM−CVD+ (abbrevia-
tions are explained in the legend to Table 3) versus 1.2
(0.7–1.9) among DM+CVD− and 6.7 (3.0–14.9) among
DM+CVD+ (p-value for the difference between DM−CVD+
and DM+CVD−=0.01). Among women these hazard ratios
were 3.2 (1.8–5.6) among DM−CVD+ versus 2.1 (1.4–3.2)
among DM+CVD- and 2.1 (0.5–8.8) among DM+CVD+
(p-value for the difference between DM−CVD+ and
DM+CVD−=0.14). The following additional analyses also
did not materially alter our results (data not shown):
analyses with myocardial infarction as outcome variable
instead of cardiovascular events; analyses that excluded
angina as sole cause of prior cardiovascular disease
(because angina may be a poor marker of coronary heart
disease among women); analyses that excluded partici-
pants with newly detected diabetes; and analyses with
additional adjustment for duration of diabetes.
Discussion
This study is the first to compare the risk of cardiovascu-
lar events in individuals with type 2 diabetes to that of
nondiabetic individuals with and without prior cardiovas-
cular disease, and to assess whether these comparisons
were affected by gender. Our results suggest that the
concept of Haffner et al., that individuals with diabetes
but without prior myocardial infarction have a cardiovas-
cular mortality risk that is of similar magnitude as that of
individuals without diabetes but with prior myocardial
infarction,5 cannot be generalised to all populations. We
found that gender strongly modified the associations
between diabetes and cardiovascular events. In analyses
stratified for gender, the hazard ratio of cardiovascular
disease of women with diabetes but without prior cardio-
vascular disease was indeed similar to that of women
without diabetes but with prior cardiovascular disease.
However, for fatal cardiovascular disease, this risk was
actually higher among women with diabetes but without
prior cardiovascular disease than among women without
diabetes but with prior cardiovascular disease. In con-
trast, the risk of cardiovascular disease among men with
diabetes but without prior cardiovascular disease was
Fig. 1 Kaplan–Meier estimates of the proportion of individuals without
cardiovascular events, stratified for diabetes and prior cardiovascular
disease. DM− or + denotes the absence or presence of type 2 diabetes
mellitus and CVD− or + the absence or presence of prior cardiovascular
disease at baseline.
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substantially lower than that of men without diabetes
but with prior cardiovascular disease. Although the con-
fidence intervals around some of these hazard ratios
were rather wide, they clearly and significantly differed
between men and women. Adjustment for potential
confounders did not alter these results.
Haffner et al. found a similar risk for mortality from
coronary heart disease for individuals with diabetes but
without prior myocardial infarction as for individuals
without diabetes but with prior myocardial infarction.
Their study did not report analyses for men and women
separately, but if we assume that results in their study
were not affected by gender, then our results differ
markedly from theirs. We used a different definition of
prior cardiovascular disease than did Haffner et al., but
this is unlikely to explain the differences in results. When
we analysed our results according to the presence of
prior myocardial infarction instead of prior cardiovascu-
lar disease, the hazard ratios were not importantly
altered, although the confidence intervals became wider
(data not shown). Another possible explanation for the
observed differences between our study and Haffner et
al.’s study may be that we included participants with
newly detected diabetes. However, exclusion of these
participants from the analyses did not materially alter
our results (data not shown). Taken together, the differ-
ences in the participants’ clinical characteristics and in
the definition of prior cardiovascular disease between
Table 3 Hazard ratios for fatal and nonfatal cardiovascular events associated with type 2 diabetes and/or prior cardiovascular
disease
MEN DM−CVD− DM-CVD+ DM+CVD− DM+CVD+
First cardiovascular event 145 79 18 12
Event ratea 2.1 7.1 4.0 9.0
Cases (n) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Model 1 1.0 2.8 (2.1–3.7)b 1.4 (0.9–2.3) 5.7 (3.1–10.3)b
Model 2 1.0 2.2 (1.7–3.0)b 1.3 (0.7–2.1) 4.3 (1.4–8.3)b
Fatal eventsc 1.0 2.4 (1.5–3.8)b 1.2 (0.5–3.1) 2.3 (0.9–6.2)
Nonfatal eventsc 1.0 2.3 (1.7–3.2)b 1.2 (0.7–.2) 4.8 (2.4–9.7)b
WOMEN DM−CVD+ DM−CVD+ DM+CVD− DM+CVD+
First cardiovascular event 93 41 25 13
Event ratea 1.1 3.5 4.0 7.8
Cases (n) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Model 1 1.0 2.7 (1.9–4.0)b 2.7 (1.8–4.3)b 6.0 (3.3–11.0)b
Model 2 1.0 2.0 (1.2–3.2)b 2.0 (1.2–3.2)a 3.8 (2.0–7.0)a
Fatal eventsc 1.0 2.6 (1.3–5.2)a 5.1 (2.6–9.9)b 6.8 (3.0–15.3)b
Nonfatal eventsc 1.0 2.0 (1.3–3.1)a 1.7 (1.0–3.0) 3.4 (1.7–7.0)b
DM+ or DM− denotes the presence or absence of type 2 diabetes; CVD+ or CVD−, the presence or absence of prior cardiovascular disease; HR=hazard
ratio; 95% CI, the 95% confidence intervals; DM−CVD− is used as reference group; *per 100 person years.
Model 1: hazard ratios of cardiovascular events adjusted to age.
Model 2: hazard ratios of cardiovascular events adjusted for age, smoking status, hypertension, low-density lipoprotein cholesterol, high-density
lipoprotein cholesterol, and triglycerides.
ap-value <0.01.
bp-value <0.001.
cModel 2.
Table 4 Hazard ratios for fatal and nonfatal cardiovascular events (as a composite variable and separately) in individuals with
type 2 diabetes without prior cardiovascular disease compared to those in nondiabetic individuals with prior cardiovascular disease
First
cardiovascular
event
Hazard ratio for
diabetic men and women
(95% CI)
p value Hazard ratio for
diabetic men
(95% CI)
p value Hazard ratio for
diabetic women
(95% CI)
p value
Model 1 0.7 (0.5–1.0) 0.08 0.5 (0.3–0.9) 0.01 1.0 (0.6–1.7) 0.91
Model 2 0.7 (0.5–1.0) 0.06 0.5 (0.3–0.9) 0.01 1.0 (0.6–1.7) 0.99
Fatal eventsa 1.0 (1.6–1.7) 0.97 0.4 (0.2–1.1) 0.07 1.7 (0.8–3.9) 0.17
Nonfatal eventsa 0.6 (0.4–1.0) 0.03 0.5 (0.2–0.9) 0.02 0.9 (0.5–1.7) 0.73
95% CI denotes the 95 percent confidence intervals,
Model 1: hazard ratios of cardiovascular events adjusted for age.
Model 2: hazard ratios of cardiovascular events adjusted for age, smoking status, hypertension, low-density lipoprotein cholesterol, high-density
lipoprotein cholesterol, and triglycerides.
aModel 2.
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the study of Haffner et al. and the present study are
unlikely to account for the observed differences in car-
diovascular risks of diabetic individuals without prior
cardiovascular disease. A recent Scottish study on this
issue suggested that patients with type 2 diabetes are at
lower risk of (cardiovascular) death or hospital admission
for myocardial infarction than patients with established
coronary heart disease.26 In our population this hypoth-
esis was confirmed among men, but not among women
with regard to cardiovascular events. Unfortunately, this
study did not compare risks conferred by diabetes or
myocardial infarction for men and women separately.
One potential explanation for the discrepancies between
the findings in these studies is that there may be true
heterogeneity among populations, that is, gender may
modify the associations between type 2 diabetes and
cardiovascular mortality in some populations but not in
others.
The finding that, for men, the presence of diabetes
did not notably increase the hazard ratio of cardiovascu-
lar events is remarkable, but has been reported before in
two large studies,9,27 although other studies did find a
higher risk.6,11,28 Our finding that the hazard ratio of
cardiovascular mortality associated with the presence of
diabetes was higher among women than men is consistent
with previous observations.3,12,13 Other cardiovascular
risk factors did not explain the greater vulnerability of
women than men with type 2 diabetes in the present
study. We considered several other possible explana-
tions. First, myocardial infarction has a higher case
fatality rate in patients with than in patients without
diabetes,29 so if myocardial infarctions would have a
higher case fatality rate in women with diabetes than in
men with diabetes, this could explain the difference in
cardiovascular mortality risk between the sexes. Previous
studies do not support this hypothesis, 30–33 but, on the
basis of our data, we can neither reject nor confirm this
possibility. Second, a better treatment for men than for
women with diabetes, especially after a first cardiovas-
cular event, could to some extent explain the worse
cardiovascular survival for women than for men. At first
glance, this is not likely in our population because,
among individuals with known diabetes at baseline, the
frequency of medical treatment for diabetes, hyperten-
sion and/or dyslipidaemia was similar for men and
women (91.4% vs 92.7%), but this issue requires further
study, because we were unable to analyse whether treat-
ment differed during follow-up. Third, Barrett-Connor
et al.12 and others34 have suggested that the higher
relative cardiovascular mortality risk of women with
diabetes is largely a function of their superior survival in
the absence of diabetes. This is also evident in our study:
women without diabetes had a lower cardiovascular
mortality risk compared to men without diabetes. In
addition, the absolute cardiovascular mortality risk
among women with diabetes was higher than that in men
with diabetes. Therefore, the higher hazard ratio of
cardiovascular mortality among women than men with
diabetes in our study was a function of both the low
absolute risk among women without diabetes and the
high absolute risk among women with diabetes.
The biological basis for our findings remains to be
clarified. We speculate that one or more cardiovascular
risk factors associated with type 2 diabetes interact with
female gender to increase the risk of atherothrombotic
disease. For example, it has been shown that insulin
resistance is more strongly associated with arterial
stiffness in women than in men.35,36
There are several potential limitations to our study.
We studied a Caucasian population, so the question
remains whether our conclusions can be generalised to
other ethnic groups. Furthermore, we studied individuals
aged 50 to 75 at baseline and we cannot exclude the
possibility that men with diabetes had already died
before the age of 50, thus potentially underestimating
the mortality risk of men with diabetes. However, this is
improbable because the prevalence of diabetes is rela-
tively low among individuals under 50.37 A third short-
coming may be that information about prior
cardiovascular disease was self-reported. Therefore,
some misclassification might exist. However, such mis-
classification is likely to be nondifferential and therefore
cannot explain the gender differences we observed.
Finally, men and women may report symptoms differ-
ently. However, since men and women were analysed
separately, bias is most likely limited and only occurs
when men and women are compared. The prevalence of
angina pectoris was 5.0% among men and 5.7% among
women. These percentages do not differ significantly
(p-value of the difference=0.4).
In conclusion, we compared, among individuals with
and without prior cardiovascular disease, the risk of
cardiovascular events associated with type 2 diabetes.
The risk varied substantially between the sexes: it was
considerably higher in women than in men. These data
emphasise the necessity of aggressive treatment of
cardiovascular risk factors in women with type 2
diabetes.
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